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In this issue of Immunity, Darce et al. (2012) and Bettini et al. (2012) demonstrate that seemingly subtle alter-
ations in the interaction of Foxp3 with its transcriptional partners have a ripple effect on the outcome of auto-
immune phenotypes, worsening some while ameliorating others.The transcription factor Foxp3 controls
myriad regulatory T (Treg) cell functions
by virtue of its capacity to engage
numerous other cofactors that array along
the length of the protein in a series of
molecular modules (Josefowicz et al.,
2012). Disruption of one or more of those
modules by missense mutations or in-
frame deletions in FOXP3, as seen in
human subjects with the IPEX syndrome,
results in the emergence of systemic auto-
immunity and inflammation (Torgerson and
Ochs, 2007). In this issue of Immunity, two
groups report that a commonly used
murine Foxp3 reporter allele (Foxp3tm2Ayr),
encoding a Foxp3 protein that is fused at
its N-terminus to the enhanced green fluo-
rescence protein (EGFP), exhibits distinct
phenotypes on different murine genetic
backgrounds prone to autoimmunity, thus
accelerating some autoimmune diseases
while suppressing others (Fontenot et al.,
2005; Darce et al., 2012; Bettini et al.,
2012). The altered function of the EGFP-
Foxp3 chimera relates to the impact of
the fused EGFP on the interaction of
N-terminal Foxp3domainwithother cofac-
tors, disrupting some of those interactions
while favoring others. These serendipitous
findings shed new light on the biology of
Foxp3 and the mechanisms by which it
orchestrates distinct regulatory responses
in immune tolerance. It also serves to
emphasize both the power but also the
limitations of genetic approaches to the
study of complex biological systems, in
this case the role of Treg cells in immune
tolerance.
The pivotal role of Foxp3 to effect and
stabilize Treg cell-specific transcriptional
programs is rooted in its capacity for
molecular interactions with transcriptional
partners. These interactions organize in
modules in which different domains of
Foxp3, including the N-terminal, zincfinger, leucine zipper, and DNA binding
Forkheaddomain, interfacewith transcrip-
tional factors and regulators to form large
multiprotein complexes (Li et al., 2007).
The N terminal domain of Foxp3 engages
in interactions with transcription factors,
including IRF4, HIF1a, and RORgt, and
epigenetic regulators including TIP60 and
HDAC7 (Josefowicz et al., 2012). Foxp3-
IRF4 interactions enable Treg cells to
control Th2 cell responses, whereas the
interaction with HIF1a promotes the pro-
teasomal degradation of Foxp3 (Zheng
et al., 2009; Dang et al., 2011).
The studies of Bettini et al. took off from
the observation that Foxp3tm2Ayr allele
dramatically accelerated the develop-
ment of type 1 diabetes in disease-prone
NOD mice. In contrast, Darce et al. first
observed that the Foxp3tm2Ayr allele pro-
tected mice from autoimmune arthritis in
the K/BxN model. This prompted the later
group to examine the effects of the allele
in NOD mice, where they too observed
accelerated diabetes. Both groups then
postulated that the EGFP-Foxp3 fusion
protein altered the Treg cell transcriptional
landscape and suppressive function. De-
pendingon the tissueand themousestrain
under study, both groups also tended to
observe a decrease in the frequency of
Treg cells expressing the mutant allele
relative to control Treg cells, as well as
an increase in the mutant protein. These
changes began in the thymus, suggesting
an impact of the mutant allele on Treg cell
development.
In addition to its impact on Treg cell
development in the thymus and peripheral
homeostasis, Bettini et al. found that the
mutant allele also affected the generation
of induced Treg (iTreg) cells, a subset that
arises from naive conventional T cells in
a TGF-beta-dependent manner and are
required for tolerance (Haribhai et al.,Immunity2011; Bilate and Lafaille, 2012). In
a related observation, Darce et al. found
that the mutant allele decreased the
frequency of Th17 cells in the small intes-
tinal lamina propria, an effect that may be
linked to an altered capacity of Treg cells
expressing the Foxp3tm2Ayr allele to
suppress Th17 cell generation. These
observations have relevance to studies
that employ the Foxp3tm2Ayr allele in the
analysis of inflammatory and tolerogenic
responses to exogenous antigens and
the microbial flora at the environmental
interfaces.
In examining the impact of the
Foxp3tm2Ayr allele on Treg cell function in
the context of autoimmune responses,
an unusually nuanced picture emerged.
Although it accelerated the autoimmune
diabetes in NOD mice and bowel inflam-
mation in lymphopenia-colitis models,
the Foxp3tm2Ayr allele proved to be protec-
tive against experimental autoimmune
arthritis in the K/BN model, reinforcing
the dictum that not all tolerance is created
equal. Here, the studies by the two groups
diverged to consider different potential
mechanisms by which the Foxp3tm2Ayr
allele alters Treg cell functions (Figure 1).
Darce et al. focused on the apparent
dichotomy that the Foxp3tm2Ayr allele pro-
tected against antibodymediated autoim-
munity in the K/BxN mouse model of
arthritis even as it worsened the type 1
diabetes in NOD mice. They related both
observations to alterations in the interac-
tion of the EGFP-fusion protein with IRF4
and HIF1a. By disfavoring the interaction
with HIF1a, and consequently antago-
nizing HIF1a-dependent degradation of
Foxp3, the EGFP moiety tipped the
balance in favor of IRF4 interaction, re-
flected in a Treg cell transcriptome
enriched in IRF4-regulated transcripts.
Their proposal of subtle alterations in36, May 25, 2012 ª2012 Elsevier Inc. 693
N-terminal 
Zinc finger
C-terminal 
Leucine zipper Fork-head
Hif1a
Tip60 HAT
HDAC7
p300 HAT
Eos
IRF-4
AML-1 NF-AT
Zinc finger
EGFP
Leucine zipper Fork-head
p300 HAT
Eos
IRF-4
AML-1 NF-AT
Foxp3
EGFP-Foxp3
Cofactor-dependent
transcriptional program
Altered epigenetic signature 
Biased transcriptional program 
Increased EGFP-Foxp3 protein expression
Figure 1. Altered Functions of EGFP-Foxp3 Fusion Protein
Interactions of the N-terminal domain of the native Foxp3 protein with different cofactors (top). Dimeric
Foxp3 proteins interact at their N-termini with a number of transcriptional factors and regulators, including
among others the transcription factors Hif1a, IRF4, and Eos, the histone acetyltransferases (HATs) Tip60
and p300, and the histone deacetylase HDAC7. These interactions enable a number of cofactor-
dependent transcriptional circuitries and help regulate the levels of Foxp3 protein. Altered N-terminal
domain interactions and Treg cell responses induced by the EGFP-Foxp3 fusion protein (bottom). The
introduction of an N-terminal EGFP alters the interaction of the EGFP-Foxp3 fusion protein with the
different co-factors, invigorating some interactions (e.g., with IRF4) while weakening or abolishing others
(e.g., those with HATs, Eos, and Hif1a). These alterations impact the transcriptional landscape of Treg
cells, potentiating their capacity to enforce tolerance against some autoimmune responses (e.g., auto-
antibody production in the K/BxN arthritis model) while weakening their response to others (e.g.,
Th1-driven type 1 diabetes in the NOD mouse).
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a dramatic impact on the regulation by
Treg cells of different modalities of auto-
immunity, such as Th1 cell-dependent
type 1 diabetes versus Th2 and Th17
cell-dependent autoantibody-dependent
arthritis, is very provocative and will prob-
ably pique further interest in how different
transcriptional modules of Foxp3 regulate
distinct facets of autoimmunity.
Bettini et al. also observed altered inter-
action of the N-terminal domain of the
EGFP-Foxp3 chimera, with decreased
interaction with a number of cofactors
involved in the regulation of gene ex-
pression by Foxp3, including the zinc
finger-type transcription factor Eos, the
histone acetyl transferases Tip60 and
p300, and the histone deacetylase
HDAC7. They hypothesized that impair-
ment of these interactions affected the
stability of Foxp3 at sites of inflammation,
in part by instigating decreased acetyla-
tion and increased polyubiquitination of
the EGFP-Foxp3 fusion protein. The
failure of these cofactors to effectively
engage the N-terminus of the EGFP-
Foxp3 fusion protein also altered the
Treg cell transcriptome in a manner that
impaired the Treg cell response at those694 Immunity 36, May 25, 2012 ª2012 Elseviinflammatory sites. Although the pro-
posed mechanisms for the Treg cell
dysfunction associated with the EGFP-
Foxp3 fusion protein are not exclusive,
more studies are required to clarify the
relative contribution of the respective
mechanism(s) to the observed pheno-
types associated with the mutant protein.
More broadly, these findings suggest
potentially wider perturbations in the
function of other subsets of Treg cells,
such as lymph node follicular Treg cells
and mucosal iTreg cells, that may be rele-
vant to the observed phenotypes.
Previous studies employing the
Foxp3tm2Ayr allele have been instrumental
in illuminating the biology of Treg cells
and in probing the various functions of
Foxp3 in transcriptional regulations. Many
of these findings have been independently
confirmed by several groups using other
genetic and reporter allele models of
Foxp3 function. Nevertheless, the over-
whelming majority of the studies employ-
ing the Foxp3tm2Ayr allele were carried out
on the non-autoimmune prone C57BL/6
background, and the results discussed
herein indicate that caution should be ex-
ercised when extending some of those
studies to other genetic strains. Addi-er Inc.tionally, earlier results obtained with the
Foxp3tm2Ayr allele need to be carefully
considered in at least two other situations.
The first is in regards to the employment
of the EGFP-Foxp3 chimera in studies on
iTreg cells, whose development it may
impair. The second relates to studies on
compound mutations that are either in cis
at other sites in the Foxp3 locus or in trans
with other genes (e.g., combination of
the Foxp3tm2Ayr allele and other knockin-
knockout alleles such as those targeting
transcription factors relevant to Treg
cell function). Unaccounted interac-
tions between such mutations, although
interesting in their own right, may cloud
the interpretations of the resultant
phenotypes.
Finally, it is worth recalling that the deri-
vationofanygeneticallyengineeredanimal
model entails a compromise between
faithfully reproducing the phenomenon
under study while acknowledging an
impact, however minor, of the alterations
introduced by the genetic engineering on
the results thus obtained. This reenact-
ment of the uncertainty principle should
not be far from the mind of investigators
employing those models in their studies.
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